Debt-to-equity of Evofem Biosciences, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Evofem Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Evofem Biosciences, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -116%, a 3.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Evofem Biosciences, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -116% -4.2% -3.8% 30 Sep 2025
Q2 2025 -120% -10% -9.5% 30 Jun 2025
Q1 2025 -118% -3.7% -3.3% 31 Mar 2025
Q4 2024 -116% +8.3% +6.7% 31 Dec 2024
Q3 2024 -112% +20% +15% 30 Sep 2024
Q2 2024 -109% +32% +22% 30 Jun 2024
Q1 2024 -114% +21% +15% 31 Mar 2024
Q4 2023 -125% +6.1% +4.7% 31 Dec 2023
Q3 2023 -132% -0.82% -0.62% 30 Sep 2023
Q2 2023 -141% -3.8% -2.8% 30 Jun 2023
Q1 2023 -135% +52% +28% 31 Mar 2023
Q4 2022 -131% +153% +54% 31 Dec 2022
Q3 2022 -131% +580% +82% 30 Sep 2022
Q2 2022 -137% -1188% -113% 30 Jun 2022
Q1 2022 -187% -554% -151% 31 Mar 2022
Q4 2021 -283% -519% -220% 31 Dec 2021
Q3 2021 -711% -843% -637% 30 Sep 2021
Q2 2021 1051% +951% +956% 30 Jun 2021
Q1 2021 367% +288% +362% 31 Mar 2021
Q4 2020 236% +68% +40% 31 Dec 2020
Q3 2020 132% -1082% -89% 30 Sep 2020
Q2 2020 99% +489% 30 Jun 2020
Q1 2020 79% +264% 31 Mar 2020
Q4 2019 168% +384% 31 Dec 2019
Q3 2019 1214% +1271% 30 Sep 2019
Q2 2019 -390% 30 Jun 2019
Q1 2019 -185% 31 Mar 2019
Q4 2018 -217% 31 Dec 2018
Q3 2018 -57% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.